This page shows the latest Dupixent news and features for those working in and with pharma, biotech and healthcare.
At 16 weeks, 68% of children on the higher dose, and 58% on the lower dose of Dupixent ‘achieved the primary endpoint of significant histological disease remission’. ... Dupixent is a fully human monoclonal antibody that inhibits the signalling of
Dupixent would be the first drug specifically indicated for the condition in the US. ... In both PRIME and PRIME2, the primary and key secondary endpoints were met and showed Dupixent significantly improved disease signs and symptoms versus placebo.
Dupixent is the first and only drug specifically recommended for EoE in the US. ... Following the FDA’s decision, Dupixent has become the first and only available medicine specifically recommended for the treatment of EoE in the US.
Dupixent is suitable for 6- to 11-year-old children who have severe asthma and type 2 inflammation. ... Dupixent significantly reduces asthma attacks, helps children breathe better and improves their health-related quality of life.”.
It was shown that Dupixent significantly reduced itch and skin lesions compared to placebo in both trials. ... times as many Dupixent patients experienced a clinically meaningful reduction in itch from baseline at week 24.
Sanofi and Regeneron Pharmaceuticals have announced positive results from a second phase 3 trial, showing Dupixent (dupilumab) – when administered in 300mg doses weekly – significantly improved the signs and symptoms of eosinophilic ... Additionally,
More from news
Approximately 28 fully matching, plus 34 partially matching documents found.
Dupixent for eczema and asthma – in order to ramp up internal generation of new drug candidates.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Videum Health is a premium video platform that offers brands innovative engagement strategies to reach targeted healthcare audiences on a...